Combating susceptibility to drug resistance: Lessons from HIV-1 protease

Chemistry and Biology

Volumn 11, Issue 10, 2004, Pages 1333-1338

  King, Nancy M ^a   Prabu Jeyabalan, Moses ^a   Nalivaika, Ellen A ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; PHYSIOLOGY; SYNTHESIS;

BINDING SITES; DRUG RESISTANCE, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HIV PROTEASE; HIV PROTEASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 5444247213     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.08.010     Document Type: Article

References (26)

1. Erickson J.W. The not-so-great escape. Nat. Struct. Biol. 2:1995;523-529
2. Coffin J.M. HIV population dynamics in vivo. implications for genetic variation, pathogenesis and therapy Science. 257:1995;483-489
3. Roberts J.D., Bebenek K., Kunkel T.A. The accuracy of reverse transcriptase from HIV-1. Science. 242:1988;1171-1173
4. Roberts J.D., Preston B.D., Johnston L.A., Soni A., Loeb L.A., Kunkel T.A. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol. Cell. Biol. 9:1989;469-476
5. Ji J.P., Loeb L.A. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry. 31:1992;954-958
6. Prabu-Jeyabalan M., Nalivaika E., Schiffer C.A. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301:2000;1207-1220
7. Prabu-Jeyabalan M., Nalivaika E.A., Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease. Analysis of crystal structures of six substrate complexes Structure. 10:2002;369-381
8. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:1996;3763-3769
9. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:1997;6662-6670
10. Bally F., Martinez R., Peters S., Sudre P., Telenti A. Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites. clinical significance and implications for resitance to protease inhibitors AIDS Res. Hum. Retroviruses. 16:2000;1209-1213
11. La Seta Catamancio S., De Pasquale M.P., Citterio P., Kurtagic S., Galli M., Rusconi S. In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure. J. Clin. Microbiol. 39:2001;1124-1129
12. Forstenlehner M. Aids. new fda-approved agents Pharm. Unserer Zeit. 29:2000;58
13. Temesgen Z. Current status of antiretroviral therapies. Expert Opin. Pharmacother. 2:2001;1239-1246
14. Shafer R.W., Stevenson D., Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27:1999;348-352
15. Shafer R.W., Hsu P., Patick A.K., Craig C., Brendel V. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J. Virol. 73:1999;6197-6202
16. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., Shafer R.W. Mutation patterns and structural correlates in HIV-1 protease following varying degrees of protease inhibitor treatment. J. Virol. 77:2003;4836-4847
17. Prabu-Jeyabalan M., Nalivaika E.A., King N.M., Schiffer C.A. Viability of a drug-resistant HIV-1 protease variant. structural insights for better anti-viral therapy J. Virol. 77:2003;1306-1315
18. Prabu-Jeyabalan M., King N.M., Nalivaika E., Schiffer C.A. Coevolution of the Nucleocapsid-p1 cleavage site with the V82A mutation in HIV-1 protease preserves substrate recognition. J. Virol. in press:2004
19. King N.M., Prabu-Jeyabalan M., Wigerinck P., De Bethune M.-P., Schiffer C.A. The structural and thermodynamic basis for the binding of a next generation HIV-1 protease inhibitor, TMC114. J. Virol. in press:2004
20. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, A potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1995;1181
21. Chen Z., Li Y., Chen E., Hall D.L., Darke P.L., Culberson C., Shafer J.A., Kuo L.C. Crystal structure at 1.9 Angstrom resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, and orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 269:1994;26344-26348
22. Krohn A., Redshaw S., Ritchie J.C., Graves B.J., Hatada M.H. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 34:1991;3340-3342
23. Kaldor S., Kalish V., Davies J.N., Shetty B., Fritz J., Appelt K., Burgess J., Campanale K., Chirgadze N., Clawson D., et al. Viracept (nelfinavir mesylate, AG1343). a potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40:1997;3979-3985
24. Stoll V., Qin W., Stewart K.D., Jakob C., Park C., Walter K., Simmer R.L., Helfrich R., Bussiere D., Kao J., et al. X-ray crystallographic structure of ABT-378 (Lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 10:2002;2803-2806
25. Ferrin T.E., Huang C.C., Jarvis L.E., Langridge R. The MIDAS display system. J. Mol. Graph. 6:1988;13-27
26. Nicholls A., Sharp K., Honig B. Protein folding and association. insights from the interfacial and thermodynamic properties of hydrocarbons Proteins. 11:1991;281-296